SCHEMBL5236246

SCHEMBL5236246

NC(=O)c1sc2nccc(N3CCCCCC3)c2c1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 14/20 1.00
CDK19 Q9BWU1 7/20 0.77
RIOK2 Q9BVS4 2/20 0.67
CSNK1A1 P48729 1/20 0.67
CSNK1D P48730 1/20 0.67
CSNK1E P49674 1/20 0.67
GSK3A P49840 1/20 0.67
HASPIN Q8TF76 1/20 0.67
LIMK1 P53667 1/20 0.59
IKBKB O14920 3/20 0.55
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
HTT P42858 3/20 0.55
HPGD P15428 2/20 0.53
HSD17B10 Q99714 2/20 0.53
USP2 O75604 1/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
TDP1 Q9NUW8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4656716 1.00 CDK8 (1.00) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL5234827 1.00 CDK8 (1.00) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL4657878 0.99 CDK8 (0.97) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL16071213 0.90 CDK8 (0.81) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL5229194 0.89 CDK8 (0.80) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL4659097 0.89 CDK8 (0.79) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL14110686 0.88 CDK8 (0.79) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL4659310 0.88 CDK8 (0.79) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL5229515 0.88 CDK8 (0.79) CDK8CDK19RIOK2CSNK1A1CSNK1D
SCHEMBL5234204 0.88 CDK8 (0.78) CDK8CDK19RIOK2CSNK1A1CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070219234-A1 Thienopyridine Derivatives SANKYO COMPANY, LIMITED (JP) 2007-09-20 US disclosed
EP-1764367-A1 THIENOPYRIDINE DERIVATIVES Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219234-A1 Thienopyridine Derivatives RASGRP1, NRAS, HRH3 CDK8 2017/4885CDK19 1842/4885RIOK2 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.